Cargando…
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
INTRODUCTION AND OBJECTIVE: COVID-19 is an ongoing, global public health crisis for which safe and effective treatments need to be identified. The benefit-risk balance for the use of lopinavir-ritonavir in COVID-19 needs to be monitored on an ongoing basis, therefore a systematic benefit-risk assess...
Autores principales: | Osborne, Vicki, Davies, Miranda, Lane, Samantha, Evans, Alison, Denyer, Jacqueline, Dhanda, Sandeep, Roy, Debabrata, Shakir, Saad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309686/ https://www.ncbi.nlm.nih.gov/pubmed/32578156 http://dx.doi.org/10.1007/s40264-020-00966-9 |
Ejemplares similares
-
Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
por: Davies, Miranda, et al.
Publicado: (2020) -
A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
por: Dhanda, Sandeep, et al.
Publicado: (2021) -
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
por: Evans, Alison, et al.
Publicado: (2020) -
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study
por: Evans, Alison, et al.
Publicado: (2020) -
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management
por: Osborne, Vicki, et al.
Publicado: (2020)